Food Diagnostics Systems Market Size, Share, Trends and Analysis

Ovarian Cancer pipeline therapeutics constitutes close to 500 molecules. Out of which approximately 443 molecules are developed by Companies and remaining by the Universities/Institutes. Global Markets Direct's latest report Ovarian Cancer – Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Ovarian Cancer Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy. The molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 15, 101, 108, 5, 183, 25 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 9, 9, 31 and 8 molecules, respectively.

Browse full report with TOC@

Furthermore, this report also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Ovarian Cancer - Pipeline Review, H1 2016...